Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Amelioration of atherosclerosis in apolipoprotein E-deficient mice by inhibition of lipoprotein-associated phospholipase A2.

Zhang H, Zhang JY, Sun TW, Shen DL, He F, Dang YH, Li L.

Clin Invest Med. 2013 Feb 1;36(1):E32-41.

PMID:
23374598
2.

Regression of atherosclerosis in apolipoprotein E-deficient mice by lentivirus-mediated gene silencing of lipoprotein-associated phospholipase A2.

Zhang H, Zhang J, Shen D, Zhang L, He F, Dang Y, Li L.

Biochem Biophys Res Commun. 2012 Oct 26;427(3):557-62. doi: 10.1016/j.bbrc.2012.09.096.

PMID:
23022183
3.

Lentiviral-mediated RNA interference of lipoprotein-associated phospholipase A2 ameliorates inflammation and atherosclerosis in apolipoprotein E-deficient mice.

Zhang H, Zhang J, Shen D, Zhang L, He F, Dang Y, Li L.

Int J Mol Med. 2013 Mar;31(3):651-9. doi: 10.3892/ijmm.2013.1248.

PMID:
23338278
4.

Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice.

Wang WY, Zhang J, Wu WY, Li J, Ma YL, Chen WH, Yan H, Wang K, Xu WW, Shen JH, Wang YP.

PLoS One. 2011;6(8):e23425. doi: 10.1371/journal.pone.0023425.

5.

The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice.

Hu MM, Zhang J, Wang WY, Wu WY, Ma YL, Chen WH, Wang YP.

Acta Pharmacol Sin. 2011 Oct;32(10):1253-8. doi: 10.1038/aps.2011.127.

6.

Darapladib.

Bui QT, Wilensky RL.

Expert Opin Investig Drugs. 2010 Jan;19(1):161-8. doi: 10.1517/13543780903501513. Review.

PMID:
20001561
7.

Regression of atherosclerosis plaques in apolipoprotein E-/- mice after lentivirus-mediated RNA interference of CD40.

Wang B, Qian H, Yang H, Xu L, Xu W, Yan J.

Int J Cardiol. 2013 Feb 10;163(1):34-9. doi: 10.1016/j.ijcard.2011.05.053.

PMID:
21640399
8.

The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.

Mohler ER 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A; Darapladib Investigators..

J Am Coll Cardiol. 2008 Apr 29;51(17):1632-41. doi: 10.1016/j.jacc.2007.11.079.

9.

Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque.

Serruys PW, García-García HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Bøtker HE, von Birgelen C, D'Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A; Integrated Biomarker and Imaging Study-2 Investigators..

Circulation. 2008 Sep 9;118(11):1172-82. doi: 10.1161/CIRCULATIONAHA.108.771899.

11.

Knockdown of mTOR by lentivirus‑mediated RNA interference suppresses atherosclerosis and stabilizes plaques via a decrease of macrophages by autophagy in apolipoprotein E‑deficient mice.

Wang X, Li L, Li M, Dang X, Wan L, Wang N, Bi X, Gu C, Qiu S, Niu X, Zhu X, Wang L.

Int J Mol Med. 2013 Nov;32(5):1215-21. doi: 10.3892/ijmm.2013.1494.

PMID:
24043133
12.

Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development.

Wilensky RL, Shi Y, Mohler ER 3rd, Hamamdzic D, Burgert ME, Li J, Postle A, Fenning RS, Bollinger JG, Hoffman BE, Pelchovitz DJ, Yang J, Mirabile RC, Webb CL, Zhang L, Zhang P, Gelb MH, Walker MC, Zalewski A, Macphee CH.

Nat Med. 2008 Oct;14(10):1059-66. doi: 10.1038/nm.1870.

13.

Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis.

Zhang J, Xu DL, Liu XB, Bi SJ, Zhao T, Sui SJ, Ji XP, Lu QH.

Yonsei Med J. 2016 Mar;57(2):321-7. doi: 10.3349/ymj.2016.57.2.321.

14.

The role of lipoprotein-associated phospholipase a₂ as a marker and potential therapeutic target in atherosclerosis.

Stewart RA, White HD.

Curr Atheroscler Rep. 2011 Apr;13(2):132-7. doi: 10.1007/s11883-010-0158-8. Review.

PMID:
21207201
15.

RNA interference of myocyte enhancer factor 2A accelerates atherosclerosis in apolipoprotein E-deficient mice.

Zhou WP, Zhang H, Zhao YX, Liu GQ, Zhang JY.

PLoS One. 2015 Mar 20;10(3):e0121823. doi: 10.1371/journal.pone.0121823.

16.

Utility of Lp-PLA2 in lipid-lowering therapy.

Racherla S, Arora R.

Am J Ther. 2012 Mar;19(2):115-20. doi: 10.1097/MJT.0b013e3181e70d32. Review.

PMID:
20634673
17.

Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.

Rosenson RS, Stafforini DM.

J Lipid Res. 2012 Sep;53(9):1767-82. doi: 10.1194/jlr.R024190. Review.

19.

Effect of darapladib treatment on endarterectomy carotid plaque lipoprotein-associated phospholipase A2 activity: a randomized, controlled trial.

Johnson JL, Shi Y, Snipes R, Janmohamed S, Rolfe TE, Davis B, Postle A, Macphee CH.

PLoS One. 2014 Feb 20;9(2):e89034. doi: 10.1371/journal.pone.0089034.

20.

Enhanced stabilization of atherosclerotic plaques in apolipoprotein E-knockout mice by combinatorial Toll-like receptor-1 and -2 gene silencing.

Qi LH, Wang Y, Gao F, Zhang C, Ding SF, Ni M, Feng JB, Zhang Y.

Hum Gene Ther. 2009 Jul;20(7):739-50. doi: 10.1089/hum.2008.203.

PMID:
19278303
Items per page

Supplemental Content

Support Center